Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains





Published: October 2013 | Pages: 81 | Format: PDF

 Summary 

 GBI Research has released its research, “Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products. GBI Research analysis shows that the APAC ophthalmology market for macular degeneration was valued at $675.7m in 2012. The market is expected to grow at a Compounded Annual Growth Rate (CAGR) of 6% for the forecast period and will reach $1,016m by 2019. Increase in the aging population and high annual cost of therapy of the marketed drugs are expected to drive the market valuations through 2019. However, the predominant off-label usage of Avastin for the treatment of the disease especially in developing countries like India and China act as a major barrier for growth of the market during the forecast period. 

 Scope 

 

  •  Disease overview along with treatment algorithms and treatment usage patterns 
  •  Market size and forecast for the macular degeneration market in APAC from 2012 to 2019 
  •  Major marketed products in the APAC along with a heat map 
  •  In-depth analysis of pipeline along with clinical trial failure analysis 
  •  Key drivers and restraints that have had a significant impact on the market 
  •  Key licensing and co-development agreements in the macular degeneration market 

 

 Reasons to buy 

 

  •  Align your product portfolio to the markets with high growth potential 
  •  Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth 
  •  Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the macular degeneration market 
  •  Develop key strategic initiatives by understanding the key focus areas and leading companies 
  •  Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships 

 

 1 Table of Contents 

 1.1 List of Tables 

 1.2 List of Figures 

 2 Macular Degeneration Asia-Pacific Market to 2019 – Introduction 

 2.1 Symptoms 

 2.2 Etiology 

 2.3 Pathophysiology 

 2.3.1 Disease Initiation 

 2.3.2 Disease Propagation 

 2.4 Classification 

 2.4.1 Early AMD 

 2.4.2 Intermediate AMD 

 2.4.3 Advanced AMD 

 2.5 Co-morbidities and Complications 

 2.6 Diagnosis 

 2.6.1 History 

 2.6.2 Examination 

 2.6.3 Diagnostic Tests 

 2.7 Epidemiology 

 2.8 Prognosis and Disease Staging 

 2.9 Treatment Options 

 2.9.1 Pharmacological 

 2.9.2 Treatment Algorithms and Prescribing Habits 

 2.9.3 Non-pharmacological Care 

 3 Macular Degeneration Asia-Pacific Market to 2019 – Marketed Products 

 3.1 Therapeutic Landscape 

 3.1.1 Lucentis (ranibizumab) – Novartis AG/Roche (Genentech) 

 3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/Bayer Healthcare 

 3.1.3 Avastin (bevacizumab) – Genentech (Roche) 

 3.1.4 Macugen (pegaptanib sodium) – Valeant Pharmaceuticals/Pfizer 

 3.1.5 Visudyne (verteporfin injection) – Novartis AG 

 3.1.6 Triamcinolone Acetonide 

 3.2 Comparative Efficacy and Safety 

 4 Macular Degeneration Asia-Pacific Market to 2019 – Pipeline for Disease 

 4.1 Overall Pipeline 

 4.2 Pipeline Analysis by Molecule Type 

 4.3 Pipeline Analysis by Mechanism of Action 

 4.4 Clinical Trials 

 4.4.1 Failure Rate 

 4.4.2 Clinical Trial Duration 

 4.4.3 Clinical Trial Size 

 4.5 Promising Drug Candidates in the Pipeline 

 4.5.1 MC-1101 – MacuCLEAR, Inc. 

 4.5.2 KH902 (Fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd. 

 5 Macular Degeneration Asia-Pacific Market to 2019 – Market Forecast to 2019 

 5.1 Geographical Markets 

 5.1.1 APAC Market 

 5.1.2 Australia 

 5.1.3 China 

 5.1.4 India 

 5.1.5 Japan 

 5.2 Drivers and Barriers for the Disease Market 

 5.2.1 Drivers 

 5.2.2 Barriers 

 6 Macular Degeneration Asia-Pacific Market to 2019 – Deals and Strategic Consolidations 

 6.1 Deals Analysis 

 6.2 Major Co-development Deals 

 6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR 

 6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners 

 6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD 

 6.2.4 Alcon Enters into Collaboration with AstraZeneca 

 6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429 

 6.3 Major Licensing Deals 

 6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy 

 6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners 

 6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma 

 6.3.4 Lpath Enters into Licensing Agreement with Pfizer 

 6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science 

 7 Macular Degeneration Asia-Pacific Market to 2019 – Appendix 

 7.1 All Pipeline Drugs by Phase 

 7.1.1 Discovery 

 7.1.2 Preclinical 

 7.1.3 IND-filed and Phase 0 

 7.1.4 Phase I 

 7.1.5 Phase II 

 7.1.6 Phase III 

 7.1.7 Undisclosed 

 7.2 Market Forecasts to 2019 

 7.2.1 Asia-Pacific 

 7.2.2 Australia 

 7.2.3 China 

 7.2.4 India 

 7.2.5 Japan 

 7.3 Market Definitions 

 7.4 Abbreviations 

 7.5 References 

 7.6 Research Methodology 

 7.6.1 Coverage 

 7.6.2 Secondary Research 

 7.6.3 Primary Research 

 7.6.4 Therapeutic Landscape 

 7.6.5 Geographical Landscape 

 7.6.6 Pipeline Analysis 

 7.7 Expert Panel Validation 

 7.8 Contact Us 

 7.9 Disclaimer 

 1.1 List of Tables 

 Table 1: Macular Degeneration Market, Classification of AMD 

 Table 2: Macular Degeneration Market, Treatment Recommendations and Follow-up for Non-neovascular AMD 

 Table 3: Macular Degeneration Market, Treatment Recommendations and Follow-up for Neovascular AMD 

 Table 4: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Discovery), 2013 

 Table 5: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 

 Table 6: Macular Degeneration Market, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013 

 Table 7: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase I), 2013 

 Table 8: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase II), 2013 

 Table 9: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase III), 2013 

 Table 10: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013 

 Table 11: Macular Degeneration Market, Asia-Pacific, Market Forecast, 2012–2019 

 Table 12: Macular Degeneration Market, Australia, Market Forecast, 2012–2019 

 Table 13: Macular Degeneration Market, China, Market Forecast, 2012–2019 

 Table 14: Macular Degeneration Market, India, Market Forecast, 2012–2019 

 Table 15: Macular Degeneration Market, Japan, Market Forecast, 2012–2019 

 1.2 List of Figures 

 Figure 1: Macular Degeneration Market, Pathophysiology of AMD 

 Figure 2: Macular Degeneration Market, Types of Dry AMD 

 Figure 3: Macular Degeneration Market, Classification of AMD 

 Figure 4: Macular Degeneration Market, Amsler Grid Test 

 Figure 5: Macular Degeneration Market, Asia-Pacific, Epidemiology, 2012–2019 

 Figure 6: Macular Degeneration Market, Photodynamic Therapy 

 Figure 7: Macular Degeneration Market, Treatment Algorithm by Type and by Stage 

 Figure 8: Macular Degeneration Market, Fluorescein Angiogram Showing Laser Photocoagulation Images 

 Figure 9: Macular Degeneration Market, Global, Annual Sales ($m), 2012 

 Figure 10: Macular Degeneration Market, Lucentis, Global, Annual Sales ($m), 2006–2012 

 Figure 11: Macular Degeneration Market, Eylea, Global, Annual Sales ($m), 2011–2012 

 Figure 12: Macular Degeneration Market, Visudyne, Global, Annual Sales ($m), 2005–2012 

 Figure 13: Macular Degeneration, Global, Heat Map of Safety and Efficacy for Marketed Products 

 Figure 14: Macular Degeneration Market, Global, Overall Pipeline, 2013 

 Figure 15: Macular Degeneration Market, Global, Pipeline Analysis by Molecule Type, 2013 

 Figure 16: Macular Degeneration Market, Global, Pipeline Analysis by Mechanism of Action, 2013 

 Figure 17: Macular Degeneration Market, Global, Clinical Trial Failure Rate, 2013 

 Figure 18: Macular Degeneration Market, Global, Pipeline, Clinical Trial Duration, 2013 

 Figure 19: Macular Degeneration Market, Global, Pipeline, Clinical Trial Size, 2013 

 Figure 20: Macular Degeneration Market, Global, Annual Sales ($bn), 2012–2019 

 Figure 21: Macular Degeneration Market, Australia, Annual Sales ($m), 2012–2019 

 Figure 22: Macular Degeneration Market, China, Annual Sales ($m), 2012–2019 

 Figure 23: Macular Degeneration Market, India, Annual Sales ($m), 2012–2019 

 Figure 24: Macular Degeneration Market, Japan, Annual Sales ($m), 2012–2019 

 Figure 25: Macular Degeneration Market, Global, Deals, 2007–2013 

 Figure 26: Macular Degeneration Market, Global, Co-development Deals, 2007–2013 

 Figure 27: Macular Degeneration Market, Global, Licensing Deals, 2007–2013 

 Figure 28: GBI Research Market Forecasting Model